Polymeric chondroitin sulfate vs. monomeric glucosamine for the treatment of osteoarthritis;Polymeres chondroitinsulfat versus monomeres glukosamin zur behandlung der arthrose

Wiener Medizinische Wochenschrift

Volumn 150, Issue 5, 2000, Pages 87-90

  Menzel, E J ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chondroitinsulfate; Glucosamine; Osteoarthritis; SPECT

Indexed keywords

CHONDROITIN SULFATE; GLUCOSAMINE; IBUPROFEN; INDOMETACIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG SAFETY; GLYCOSAMINOGLYCAN METABOLISM; HUMAN; KNEE OSTEOARTHRITIS; OSTEOARTHRITIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGGRECANS; CHONDROITIN SULFATES; EXTRACELLULAR MATRIX PROTEINS; GLUCOSAMINE; HUMANS; LECTINS, C-TYPE; MENISCI, TIBIAL; OSTEOARTHRITIS; PROTEOCHONDROITIN SULFATES; PROTEOGLYCANS; RADIOPHARMACEUTICALS; SODIUM PERTECHNETATE TC 99M; SYNOVIAL FLUID; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034103496     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. (1) Caterson B, Mahmoodian F, Sorrell JM, Hardingham TE, Bayliss MT, Carney SL: Modulation of native chondroitin sulphate structure in tissue development and in disease. J.Cell Sci. 1990;97:411-417.
2. (2) Grevitt MP, Taylor M, Churchill M, Allen P, Ryan PJ, Fogelman I: SPECT imaging in the diagnosis of meniscal tears. J Roy Soc Med 1993;86:639-641.
3. (3) Marks PH, Goldenberg JA, Vezina WC, Chamberlain MJ, Vellet AD, Fowler PJ: Subchondral bone infractions in acute ligamentous knee injuries demonstrated on bone scintigraphy and magnetic resonance imaging. J Nucl Med 1992;33:516-520.
4. (4) McCarty: Glucosamine may retard atherogenesis by promoting endothelial production of heparan sulfate proteoglveans. Med Hypotheses 1997;48:245-251.
5. (5) Menzel EJ, Runge S: Enzyme als Immunmodulatoren, Allgemeinmedizin 1990;19:140-143.
6. (6) Nakazawa M, Emancipator SN, Lamm ME: Proteolytic enzyme treatment reduces glomerular immune deposits and proteinuria in passive Heyman nephritis. J Exp Med 1986;164:1973-1987.
7. (7) Ronca F, Palmieri L, Panieucci P and G. Ronca: Anti-inflammatory activity of chondroitin sulfate. Osteoarthr Cartilage 1998;6:14-21.
8. (8) Sandy JD, Gamett D, Thompson V, Verscharen C: Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998;335:59-66.
9. (9) Steffen C, Menzel EJ: In-vivo-Abbau von Immunkomplexen in der Niere durch oral applizierte Enzyme. Wien klin Wschr 1987;99: 525-531.
10. (10) Uebelhart D, Thonar EJMA, Delmas PD, Chantraine A, Vignon E: Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthr Cartilage 1998;6:39-46.
11. (11) Uebelhart D, Thonar EJMA, Zhang J, Williams JM: Protective effect of exogenous chondroitin 4.6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthr Cartilage 1998;6:6-13.
12. (12) Verbruggen G, Goemaere S, Veys EM: Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthr Cartilage 1998;6:37-38.